Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) quinidine (HOS-085593) fusidic acid (HOS-086146) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) bepridil (HOS-085612) dronedarone (HOS-086144) alfuzosin (HOS-086139) lead (HOS-085592) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610) quinidine (HOS-085593) fusidic acid (HOS-086146) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) encainide (HOS-086145) flecainide (HOS-086203) propafenone (HOS-084530)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 16
HOS-086252 · Präparat HOS-083284
Anti-gout treatments
Colchicine Concentrations of colchicine are expected to increase when co-administered with
ritonavir.
Life-threatening and fatal drug interactions have been reported in patients treated
with colchicine and ritonavir (CYP3A4 and P-gp inhibition) in patients with renal
and/or hepatic impairment (see sections 4.3 and 4.4). Refer to the colchicine SmPC.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage eec0555c5a9458adbfa6d44b965b2adfc46a4e380106908b796a14b5664141cf · Zeichen 27474–28040 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-086440 · Präparat HOS-083284
Anti-gout treatments
Colchicine Concentrations of colchicine are expected to increase when co-administered with
ritonavir.
Life-threatening and fatal drug interactions have been reported in patients treated with
colchicine and ritonavir (CYP3A4 and P-gp inhibition) in patients with renal and/or
hepatic impairment (see sections 4.3 and 4.4). Refer to the colchicineSmPC.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9bca99de67f41a284f80758e2c533a51c80a8bb21711a5c62f318e75d2f07772 · Zeichen 28481–29046 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 5
HOS-108791 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) alfuzosin (HOS-086139) lead (HOS-085592) ranolazine (HOS-086141) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3af5f7da19ec49492414676af6b40d10b1389f87518dc00840ff964623d97870 · Zeichen 617–4755 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 42
HOS-108987 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1- Alfuzosin Increased plasma concentrations of
adrenoreceptor alfuzosin which may lead to severe
antagonist hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor
lysis syndrome at the dose initiation
and during the ramp-up phase (see
section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients
with renal and/or hepatic impairment
(see sections 4.4 and 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) amiodarone (HOS-085596) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) colchicine (HOS-086147) alfuzosin (HOS-086139) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9293fe9ecfe32956533c5b772cc23612b4a6e3a500aeb3b328481fd78b786272 · Zeichen 583–3923 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 77–78
HOS-109062 · Präparat HOS-093083
77
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and during
the ramp-up phase (see section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious arrhythmias
from these agents (see section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or
other serious adverse effects from this
agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma. The
concomitant administration with
quetiapine is contraindicated (see section
4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of ergot
ergotamine, methylergonovine derivatives leading to acute ergot toxicity,
including vasospasm and ischaemia (see
section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk of
serious arrhythmias from this agent (see
section 4.5).
Hepatitis C virus direct Elbasvir/grazoprevir Increased risk of alanine transaminase
acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylergonovine (HOS-086155) cisapride (HOS-085610) hepatitis C virus (HOS-108813) elbasvir (HOS-108814) grazoprevir (HOS-108815) alanine (HOS-088949) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) lead (HOS-085592) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage deedafd686f2a7856b9535fd14424479a75da74b88007e447ddb2a759abcc3fe · Zeichen 2941–6504 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17–18
HOS-108900 · Präparat HOS-093083
17
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of
colchicine-related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased
risk of adverse events related to
fusidic acid, notably
rhabdomyolysis (see section 4.3).
When used for osteo-articular
infections, where the co-
administration is unavoidable,
close clinical monitoring for
muscular adverse events is
strongly recommended (see section
4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline
(single dose) AUC: ↑ 22% related adverse events, the
Cmax: ↔ combination of bedaquiline and
(Lopinavir/ritonavir Kaletra should be avoided. If the
400/100 mg BID, multiple A more pronounced effect on benefit outweighs the risk,
dose) bedaquiline plasma exposures co-administration of bedaquiline
may be observed during with Kaletra must be done with
prolonged co-administration with caution. More frequent
lopinavir/ritonavir. electrocardiogram monitoring and
monitoring of transaminases is
CYP3A4 inhibition likely due to recommended (see section 4.4 and
lopinavir/ritonavir. refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f0063cdfed3d4b44f9ebbe33645572935b60d76cab70c9d2b49e5bc05279da2c · Zeichen 30589–35272 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-109013 · Präparat HOS-093083
53
benefit/risk to patient justifies the use
of voriconazole.
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg Cmax: ↑ 1.8-fold with renal and/or hepatic impairment
twice-daily) Due to P-gp and/or CYP3A4 is contraindicated due to a potential
inhibition by ritonavir. increase of colchicine-related serious
and/or life-threatening reactions such
as neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3 and
4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is recommended
in patients with normal renal or
hepatic function if treatment with
Kaletra is required. Refer to
colchicine prescribing information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline related
(single dose) AUC: ↑ 22% adverse events, the combination of
Cmax: ↔ bedaquiline and Kaletra should be
(Lopinavir/ritonavir avoided. If the benefit outweighs the
400/100 mg BID, A more pronounced effect on risk, co-administration of bedaquiline
multiple dose) bedaquiline plasma exposures with Kaletra must be done with
may be observed during caution. More frequent
prolonged co-administration with electrocardiogram monitoring and
lopinavir/ritonavir. monitoring of transaminases is
recommended (see section 4.4 and
CYP3A4 inhibition likely due to refer to the bedaquiline SmPC).
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) fusidic acid (HOS-086146) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cad5366a6fb47c00b40c65b02f661a2f3f24b27d6187e7ce6cfffb83a5f12fd8 · Zeichen 29746–34245 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89
HOS-109088 · Präparat HOS-093083
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra should
be avoided unless an assessment of
the benefit/risk to patient justifies
the use of voriconazole.
Anti-gout agents:
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of colchicine-
related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trazodone (HOS-086251) ketoconazole (HOS-084513) itraconazole (HOS-084516) voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9043d84be2324d7e08bc16eeeba0c8c1136fbb4075d51aeb08ee163e186d9cab · Zeichen 28361–32171 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114798 · Präparat HOS-094169
Co-administration of colchicine with Aptivus/ritonavir in patients with renal or hepatic impairment
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage fdb49ac9985b409a01a38bbe779b1d7a1e33243072843347c72f72205dbbc67c · Zeichen 1662–1780 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-114820 · Präparat HOS-094169
Based on theoretical
considerations, tipranavir or
ritonavir concentrations might
increase upon co-administration
with itraconazole or
ketoconazole.
Voriconazole Due to multiple CYP isoenzyme Based on the known interaction
No interaction study systems involved in voriconazole of voriconazole with low dose
performed metabolism, it is difficult to ritonavir (see voriconazole
predict the interaction with SmPC) the co-administration of
tipranavir, co-administered with tipranavir/r and voriconazole
low-dose ritonavir. should be avoided, unless an
assessment of the benefit/risk to
the patient justifies the use of
voriconazole.
Anti-gouts
Colchicine Based on theoretical A reduction in colchicine dosage
No interaction study considerations, colchicine or an interruption of colchicine
performed concentrations may increase upon treatment is recommended in
co-administration with tipranavir patients with normal renal or
and low dose ritonavir, due to hepatic function if treatment with
tipranavir/ritonavir CYP3A and Aptivus/ritonavir is required (see
P-gp inhibition. However a section 4.4).
decrease of colchicine In patients with renal or hepatic
concentrations cannot be impairment, co-administration of
excluded since both tipranavir colchicine in patients on
and ritonavir exhibit inducing
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) itraconazole (HOS-084516) ketoconazole (HOS-084513) voriconazole (HOS-084524) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 67046037b3f08c05532abf12a805568e65ce4936ee628cd887dbc1591d6d2e81 · Zeichen 19704–21833 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 14
HOS-114822 · Präparat HOS-094169
Colchicine is a substrate of
CYP3A4 and P-gp (an intestinal
efflux transporter).
Antibiotics
Clarithromycin 500 mg Clarithromycin Cmax ↔ Whilst the changes in
BID Clarithromycin AUC ↑ 19% clarithromycin parameters are not
Clarithromycin Cmin ↑ 68% considered clinically relevant, the
reduction in the 14-OH
14-OH-clarithromycin Cmax ↓ metabolite AUC should be
97% considered for the treatment of
14-OH-clarithromycin AUC ↓ infections caused by
97% Haemophilus influenzae in which
14-OH-clarithromycin Cmin ↓ the 14-OH metabolite is most
95% active. The increase of tipranavir
Cmin may be clinically relevant.
Tipranavir Cmax ↑ 40% Patients using clarithromycin at
Tipranavir AUC ↑ 66% doses higher than 500 mg twice
Tipranavir Cmin ↑ 100% daily should be carefully
monitored for signs of toxicity of
CYP 3A4 inhibition by clarithromycin and tipranavir. For
tipranavir/r and P-gp (an patients with renal impairment
intestinal efflux transporter) dose reduction of clarithromycin
inhibition by clarithromycin. should be considered (see
clarithromycin and ritonavir
product information).
Rifabutin 150 mg QD Rifabutin Cmax ↑ 70% Dosage reductions of rifabutin by
Rifabutin AUC ↑ 190% at least 75% of the usual
Rifabutin Cmin ↑ 114% 300 mg/day are recommended (ie
150 mg on alternate days, or
25-O-desacetylrifabutin Cmax ↑ three times per week). Patients
3.2 fold receiving rifabutin with Aptivus,
25-O-desacetylrifabutin AUC ↑ co-administered with low dose
21 fold ritonavir, should be closely
25-O-desacetylrifabutin Cmin ↑ monitored for emergence of
7.8 fold adverse events associated with
rifabutin therapy. Further dosage
Inhibition of CYP 3A4 by reduction may be necessary.
tipranavir/r
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147) clarithromycin (HOS-084517) Haemophilus influenzae (HOS-114823) ritonavir (HOS-084521) rifabutin (HOS-086262)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 9364d701c0760ed3d66d44141af3d15e6dce638279d23ce5ea4706d31c6562cb · Zeichen 22090–25301 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065) ritonavir (HOS-084521) cobicistat (HOS-088111) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) quinidine (HOS-085593) ranolazine (HOS-086141) ritonavir (HOS-084521) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87
HOS-116580 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) grazoprevir (HOS-108815) ergotamine (HOS-086154) methylergonovine (HOS-086155) ritonavir (HOS-084521) cobicistat (HOS-088111) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593) ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 986882b0b712a9a949916f43fb05836de98ea933859327e753cd9346903445da · Zeichen 1383–2254 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-116524 · Präparat HOS-094447
59
ANTIGOUT MEDICINES
Colchicine Not studied. Concomitant use of A reduction in colchicine dosage
colchicine and darunavir co-administered or an interruption of colchicine
with low dose ritonavir may increase the treatment is recommended in
exposure to colchicine. patients with normal renal or
(CYP3A and/ or P-gp inhibition) hepatic function if treatment with
PREZISTA co-administered with
low dose ritonavir is required. For
patients with renal or hepatic
impairment colchicine with
PREZISTA co-administered with
low dose ritonavir is
contraindicated (see sections 4.3
and 4.4).
ANTIMALARIALS
Artemether/Lumefantrine artemether AUC ↓ 16% The combination of PREZISTA
80/480 mg, 6 doses at 0, artemether Cmin ↔ and artemether/lumefantrine can
8, 24, 36, 48, and artemether Cmax ↓ 18% be used without dose adjustments;
60 hours dihydroartemisinin AUC ↓ 18% however, due to the increase in
dihydroartemisinin Cmin ↔ lumefantrine exposure, the
dihydroartemisinin Cmax ↓ 18% combination should be used with
lumefantrine AUC ↑ 175% caution.
lumefantrine Cmin ↑ 126%
lumefantrine Cmax ↑ 65%
darunavir AUC ↔
darunavir Cmin ↓ 13%
darunavir Cmax ↔
ANTIMYCOBACTERIALS
Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and
Rifapentine are strong CYP3A inducers and have PREZISTA with concomitant low
been shown to cause profound decreases dose ritonavir is not recommended.
in concentrations of other protease
inhibitors, which can result in virological The combination of rifampicin and
failure and resistance development PREZISTA with concomitant low
(CYP450 enzyme induction). During dose ritonavir is contraindicated
attempts to overcome the decreased (see section 4.3).
exposure by increasing the dose of other
protease inhibitors with low dose
ritonavir, a high frequency of liver
reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147) ritonavir (HOS-084521) artemether (HOS-116383) lumefantrine (HOS-114826) rifapentine (HOS-116386) protease (HOS-085623)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 74158b50c5b99095b0e72f07cfddcb7308a227dde01097c23cb4f0a091942901 · Zeichen 33301–36423 im Abschnitt
Gegenanzeigen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.3 · PDF-Seite 4–5
HOS-132835 · Präparat HOS-097310
4
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations
of these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions;
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): colchicine (HOS-086147) irinotecan (HOS-112102) everolimus (HOS-086310) sirolimus (HOS-085172) vardenafil (HOS-086163) paritaprevir (HOS-110301) ombitasvir (HOS-110300) ritonavir (HOS-084521) fesoterodine (HOS-116432) solifenacin (HOS-116433) tolvaptan (HOS-109429)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage faff2553122d6c384dc8d1a2a28fb45dbf0f436b1bcaa7a98bc5fee989b1cf04 · Zeichen 2103–2872 im Abschnitt
Wechselwirkungen · Ketoconazole Esteve (previously Ketoconazole HRA)
Ketoconazole Esteve 200 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-132842 · Präparat HOS-097310
o CYP3A4 metabolised HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin and lovastatin)
due to an increased risk of skeletal muscle toxicity including rhabdomyolysis;
o eplerenone due to an increased risk of hyperkalemia and hypotension;
o substances that may have their plasma concentrations increased and have QT prolonging potential :
methadone, disopyramide, quinidine, dronedarone, pimozide, sertindole, saquinavir (saquinavir/ritonavir
1000/100 mg bid), ranolazine, mizolastine, halofantrine;
o dabigatran due to an increased bleeding risk;
o triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and
respiratory depression;
o ergot alkaloids (eg dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine
(methylergonovine) due to an increased risk of ergotism and other serious vasospastic adverse
reactionsevents
o lurasidone;
o quetiapine due to an increased risk of toxicity;
o telithromycin and clarithromycin in patients with severe renal impairment due to an increased risk of
hepatotoxicity and QT interval prolongation;
o felodipine, nisoldipine due to an increased risk of oedema and congestive heart failure;
o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions;
o irinotecan due to an alteration of the metabolism of this medicinal product;
o everolimus, sirolimus (also known as rapamycin) due to an increase of the plasma concentrations of
these medicinal products;
o vardenafil in men older than 75-years due to increased risk of adverse reactions
o paritaprevir/ombitasvir (ritonavir) due to increased risk of adverse reactions;
o fesoterodine and solifenacin in patients with renal impairment;
o tolvaptan used for a specific disease called “syndrome of inappropriate antidiuretic hormone
secretion”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521) simvastatin (HOS-086158) atorvastatin (HOS-086304) lovastatin (HOS-086157) eplerenone (HOS-089050) methadone (HOS-086198) disopyramide (HOS-085595) quinidine (HOS-085593) dronedarone (HOS-086144) pimozide (HOS-085600) sertindole (HOS-085601) saquinavir (HOS-084522) ranolazine (HOS-086141) mizolastine (HOS-085609) halofantrine (HOS-085606) dabigatran (HOS-112096) triazolam (HOS-086168) midazolam (HOS-086167) alprazolam (HOS-086171) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) lurasidone (HOS-086148) quetiapine (HOS-086150) telithromycin (HOS-084523) clarithromycin (HOS-084517) felodipine (HOS-108908) nisoldipine (HOS-114251) colchicine (HOS-086147) irinotecan (HOS-112102) everolimus (HOS-086310) sirolimus (HOS-085172) vardenafil (HOS-086163) paritaprevir (HOS-110301) ombitasvir (HOS-110300) fesoterodine (HOS-116432) solifenacin (HOS-116433) tolvaptan (HOS-109429)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-05T12:00:00Z · SHA-256 1463d2e081bcaa454cdfd6129ad3b8e03e3df9233f9d0704cfceba71c89c59b5 · Passage 0b65d259964c6f340994be44a864bad55b31283e3fc412d0d5a47323a792d889 · Zeichen 171–2105 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-134441 · Präparat HOS-097580
Co-administration of darunavir with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593) ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) alfuzosin (HOS-086139) amiodarone (HOS-085596) ritonavir (HOS-084521) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0623acf1b29e890c85fc94e283370387704b0e29df5d70432cea48b4e0948b1f · Zeichen 452–1192 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.